Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.

Oncologist · 2023 · PMC10243783 · PMID 36940261

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

The biomarker studies in MORPHEUS-PDAC showed a numerical trend toward increased OS and improved HR for OS with atezolizumab plus PEGPH20 vs. control in HA-positive patients.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.